AstraZeneca Licenses Zegfrovy From Dizal for $1.5bn

AstraZeneca has agreed to pay up to $1.5bn to license global rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), an already approved EGFR inhibitor for non-small cell lung cancer (NSCLC). Announced on 14 July 2026, the deal marks the UK-listed drugmaker’s second China licensing venture in a month and adds a revenue-generating asset with strong potential for label expansion into the front-line setting.

AstraZeneca pays $600m upfront and up to $900m in milestone payments tied to development, regulatory and sales targets, with Dizal retaining tiered royalties on global sales. Zegfrovy is approved in the US (accelerated approval July 2025) and China (August 2023) for adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations who have progressed on platinum-based chemotherapy. The drug generated $83.4m for Dizal in 2025, an 85% year-on-year increase. A supplemental filing for first-line use has been submitted to both the FDA and China’s Center for Drug Evaluation.

The supplemental filing is based on Dizal’s global WU-KONG28 Phase III trial, which showed Zegfrovy improved progression-free survival versus platinum-based doublet chemotherapy in first-line NSCLC with exon 20 insertion mutations. Data was presented at ASCO 2026 and published in The New England Journal of Medicine. Currently only Johnson & Johnson’s intravenous Rybrevant plus chemotherapy has front-line approval in this NSCLC subset. Zegfrovy joins AstraZeneca’s existing lung cancer portfolio led by Tagrisso (osimertinib), which generated around $7.3bn in 2025. The deal follows AstraZeneca’s June $5.2bn CSPC Pharmaceuticals collaboration and a $15bn commitment to expand R&D and manufacturing in China.

The commercial signal is AstraZeneca doubling down on China-sourced innovation to reinforce its dominant EGFR-mutated lung cancer franchise. Following the CSPC and Dizal deals plus the $15bn China manufacturing commitment, AstraZeneca is executing on a clear thesis: Chinese biotech has become a legitimate first-tier source of oncology assets. Expect similar moves from Merck, Roche and BMS through the rest of 2026.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Katie Ginger today!